Cambridge Investment Research Advisors, Inc. Red Hill Biopharma Ltd. Transaction History

Cambridge Investment Research Advisors, Inc.

  • $29.9 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 13, 2022
SELL
$0.63 - $2.58 $16,148 - $66,130
-25,632 Closed
0 $0
Q1 2022

May 12, 2022
SELL
$1.65 - $3.12 $3,300 - $6,240
-2,000 Reduced 7.24%
25,632 $64,000
Q4 2021

Feb 03, 2022
BUY
$2.31 - $5.85 $63,829 - $161,647
27,632 New
27,632 $71,000

Others Institutions Holding RDHL

# of Institutions
2
Shares Held
40.4K
Call Options Held
0
Put Options Held
0
View Full List

About RedHill Biopharma Ltd.

RDHL Quotes by TradingView
  • Ticker RDHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 63,823,500
  • Market Cap $192M
  • Description
  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...
More about RDHL
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email